Endoscopic Submucosal Dissection Followed by Concurrent Chemoradiotherapy in Patients with Early Esophageal Cancer with a High Risk of Lymph Node Metastasis
- Author:
Hee Kyung KIM
1
;
Weon Jin KO
;
Chang Il KWON
;
Ga Won SONG
;
In Kyun YOO
;
Ji Hyun SONG
;
Hak Su KIM
;
Joo Young CHO
Author Information
- Publication Type:Case Report
- Keywords: Early esophageal cancer; Concurrent chemoradiotherapy; Endoscopic submucosal dissection
- MeSH: Chemoradiotherapy; Esophageal Neoplasms; Follow-Up Studies; Humans; Lymph Nodes; Neoplasm Metastasis; Prospective Studies; Recurrence; Survival Rate
- From:Clinical Endoscopy 2019;52(5):502-505
- CountryRepublic of Korea
- Language:English
- Abstract: Endoscopic submucosal dissection is recommended as an alternative therapy for early esophageal cancer. However, achieving curative resection in this procedure remains controversial since precise prediction of lymph node metastasis can be difficult. Here, we present the preliminary results of endoscopic submucosal dissection followed by concurrent chemoradiotherapy for early esophageal cancer with a high risk of lymph node metastasis. From May 2006 to January 2014, six patients underwent concurrent chemoradiotherapy after endoscopic submucosal dissection with a median follow-up period of 63 months. No complications were encountered during concurrent chemoradiotherapy. Although local recurrence did not occur in all patients, two patients were diagnosed with metachronous cancer. Overall, the survival rate was 100%. Thus, endoscopic submucosal dissection followed by concurrent chemoradiotherapy may be a feasible treatment for early esophageal cancer in patients with a high risk of lymph node metastasis. Future prospective large-scale studies are warranted to confirm our results.
